Chonluten

Key points

• Chonluten is a very short peptide, one of a family of bioregulators each aimed at a particular organ.
• It is marketed to support the lungs and airways.
• Almost all the research comes from a single group, and independent evidence is lacking.
• It is not a licensed medicine in the UK and is sold for research use.

Quick facts

What it is

Peptide bioregulator (lungs and airways)

Marketed for

Lung and airway support

UK status

Not a licensed medicine; sold for research use

Human evidence

Mostly from one research group

How it works

The idea behind the bioregulators is that short peptides can act as signals that help a particular tissue work normally. Chonluten is aimed at the lungs and airways. How well this works in people, and exactly how, is not established outside its country of origin.

What the evidence shows

There are studies from Russia reporting benefits for the respiratory system, but independent trials of the kind needed to license a medicine in the UK are lacking. The claims should be treated with caution.

What it does not settle

• Independent evidence outside its country of origin is limited.
• Long term safety in wide use is not well established.
• Products sold online are not quality assessed.

Side effects

Less common but serious

• Because there is no UK licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

Chonluten has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use.

Common questions